Gubra Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Gubra's estimated annual revenue is currently $27.7M per year.
- Gubra's estimated revenue per employee is $155,000
- Gubra has 179 Employees.
- Gubra grew their employee count by 34% last year.
- Gubra currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
What Is Gubra?
Founded in 2008, we are a privately-held biotech company with two primary areas of business: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. Our focus is the metabolic space (obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We work with some of the most interesting and loyal partners and customer from across the world within big pharma, biotech and academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.keywords:N/A
Number of Employees
Employee Growth %
Two years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a higher level.
German pharma major Boehringer Ingelheim and Danish biotech Gubra have announced a second collaboration and license agreement for ...
INGELHEIM, Germany & HØRSHOLM, Denmark--(BUSINESS WIRE)--Boehringer Ingelheim and Gubra announce a second collaboration and ...